Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 4, 1996, Pages 352-361

  Tubergen, David G ^a,i   Stewart, Clinton F ^b   Pratt, Charles B ^b   Zamboni, William C ^b   Winick, Naomi ^c   Santana, Victor M ^b   Dryer, Zo Anne ^d   Kurtzberg, Joanne ^e   Bell, Beverly ^f   Grier, Holcombe ^g   Vietti, Teresa J ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Pediatric Oncology Group   (United States)

Author keywords

Children; Pharmacodynamics; Pharmacokinetics; Phase I; Solid tumors; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; EWING SARCOMA; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIESIS; HUMANS; MALE; NEOPLASMS; TOPOTECAN;

EID: 10244270659     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199611000-00004     Document Type: Article

References (20)

1. Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs (in press).
2. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-5.
3. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
4. Von Hoff DD, Burris HA, Eckardt J, et al. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994;34:S41-5.
5. Wall JG, Burris HA, Von Hoff DD, et al. A phase I clinical and pharmacologic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-45.
6. O'Dwyer PJ, LaCreta FP, Haas NB, et al. Clinical pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994;34:S46-52.
7. van Warmerdam LJ, Verweij J, Schellens JH, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35: 237-45.
8. Haas NB, LaCreta FP, Walczak J, et al. Phase I/pharmacokinetics study of topotecan by 24-hour continuous infusion weekly. Cancer 1994;54:1220-6.
9. Kantarjian HM, Beran M, Ellis A, et al. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory of relapsed acute leukemia. Blood 1993;81:1146-51.
10. Rowinsky EK, Adjei A, Donehower RC, et al. Phase I and pharmaco-dynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193-203.
11. Rowinsky EK, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
12. Saltz L, Sirott M, Young C, et al. Phase I trial and clinical pharmacologic study of intravenous topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-507.
13. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993;53:1032-6.
14. Pratt CB, Stewart C, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
15. D'Argenio DZ, Schumitzky A. ADAPT II user's guide. USC, Los Angeles: Biomedical Simulations Resource, 1990.
16. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994;12:1946-54.
17. Slichenmyer WJ, Rowinsky EK, Grochow LB, et al. Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 1994;43:S53-7.
18. Hashimoto Y, Sheiner LB. Designs for population pharmacodymamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991;19:333-53.
19. van Warmerdam LJC, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994;5:259-64.
20. Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure to topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia. J Clin Oncol 1996;14: 1504-11.